Ozempic is generally well tolerated, but it carries real risks that vary depending on your health history, how fast you lose weight, and how long you stay on it. The most important thing to know upfront: Ozempic is not actually FDA-approved for weight loss. It’s approved for type 2 diabetes and cardiovascular risk reduction in diabetic patients. When doctors prescribe it for weight loss, they’re using it off-label. A higher-dose version of the same drug, Wegovy, is the one approved specifically for obesity. The active ingredient in both is semaglutide.
That distinction matters because the safety data, dosing schedules, and monitoring protocols differ between the two uses. Here’s what the evidence says about the risks you should actually weigh.
Common Side Effects Are Digestive
The side effects most people experience are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are not rare complications. They’re the expected result of how the drug works, slowing the movement of food through your stomach and gut. For most people, these symptoms are worst during the first few weeks and improve as the body adjusts.
To minimize these effects, semaglutide is prescribed on a gradual dose escalation schedule. You start at 0.25 mg once weekly for the first four weeks, then move to 0.5 mg, then 1 mg, increasing roughly every four weeks. If a dose increase hits you hard, your prescriber can delay the next step by an additional four weeks. Skipping this ramp-up and jumping to a higher dose significantly increases the likelihood of severe nausea and vomiting.
Gastroparesis Risk Is Higher Than Expected
One risk that’s gotten increasing attention is gastroparesis, a condition where the stomach empties far too slowly, causing persistent nausea, bloating, and vomiting that can continue even after stopping the drug. A retrospective study of over 55,000 people with obesity (without diabetes) found that the rate of gastroparesis in semaglutide users was 6.5 per 1,000 person-years. That’s roughly three times higher than the rate seen with another weight loss medication (bupropion-naltrexone) and about six times higher than in people who had sleeve gastrectomy surgery.
This doesn’t mean gastroparesis is common in absolute terms. Most people won’t develop it. But the elevated risk is notable, especially for anyone who already has slow digestion or motility issues.
The Thyroid Cancer Warning
Ozempic carries the FDA’s most serious warning, a boxed warning, about thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid tumors at doses comparable to human use. Whether this translates to humans remains unknown. The FDA’s label states plainly: “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.”
Because of this uncertainty, semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If you have either, this drug is off the table entirely. For everyone else, be aware of symptoms like a lump in the neck, difficulty swallowing, or persistent hoarseness, and report them promptly.
Pancreatitis and Gallbladder Problems
Acute pancreatitis, an intensely painful inflammation of the pancreas, has occurred in semaglutide users. In one weight loss trial, 3 out of 1,306 participants on semaglutide developed it, compared to zero out of 655 on placebo. A larger meta-analysis across multiple semaglutide trials found no statistically significant increase in pancreatitis risk overall, with an odds ratio of 0.7, meaning the signal is small and inconsistent.
Gallstones are a more straightforward concern. Semaglutide slows the movement of bile through the gallbladder, which can lead to sludge and stone formation. This risk is compounded by rapid weight loss itself. Losing more than about 3.3 pounds per week, or losing more than 25% of your body weight, independently raises gallstone risk regardless of which method you used to lose the weight. The combination of the drug’s effect on bile motility and fast weight loss creates a situation worth monitoring, particularly if you’ve had gallbladder issues before.
Muscle and Lean Mass Loss
Weight lost on semaglutide isn’t purely fat. Research from the University of Utah found that semaglutide-induced weight loss decreased lean mass by about 10% in animal models. Individual skeletal muscles shrank by roughly 6% on average. The researchers cautioned against directly applying mouse data to humans, since the two species gain and lose weight differently, but the concern about losing functional muscle alongside fat is a practical one.
This is relevant because losing muscle mass can reduce your metabolic rate, making weight regain more likely if you stop the medication. It also affects strength, balance, and long-term mobility, especially in older adults. Resistance training and adequate protein intake during treatment are widely recommended to counteract this effect, though clinical trials specifically testing those strategies alongside semaglutide are still limited.
Mental Health and Suicidal Thoughts
Reports of suicidal thoughts in people taking GLP-1 drugs prompted an FDA investigation that has been ongoing for over two years. As of January 2026, the FDA’s conclusion is that the available evidence does not show a clear link between these drugs and suicidal ideation. Reviews of adverse event reports, clinical trials, and observational studies all came back without a demonstrated association.
However, the FDA hasn’t closed the case. Because the number of suicidal events in both drug and placebo groups was small, the agency says it “cannot definitively rule out that a small risk may exist.” The prescribing information for semaglutide when used for weight loss already includes language about suicidal thoughts, which is standard for weight loss medications broadly, not specific to this drug class.
Who Should Avoid Semaglutide
Beyond the thyroid cancer contraindication, semaglutide should not be used by anyone with a history of serious allergic reaction to the drug or its inactive ingredients. People with a history of pancreatitis should use caution, and the FDA label suggests considering alternative treatments for those patients. It’s also not approved or studied for use in people with type 1 diabetes.
The safety profile changes meaningfully depending on your individual risk factors. Someone with a healthy gallbladder, no thyroid history, and no digestive motility issues faces a different risk calculus than someone with prior gallstones and a family history of thyroid cancer. The drug is not universally dangerous, but it’s also not risk-free, and the off-label nature of using Ozempic specifically for weight loss means you may not be getting the dose titration schedule or monitoring designed for that purpose.